Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16699925 | 0.79 | CSNK1D (0.51) | CSNK1DCSNK1E | |
| SCHEMBL16699032 | 0.72 | ADORA3 (0.37) | KDM4EHTTALDH1A1HPGDTSHR | |
| SCHEMBL16728669 | 0.69 | KMT2A (0.36) | KDM4EL3MBTL1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL16700630 | 0.66 | KMT2A (0.35) | KDM4EL3MBTL1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL16711267 | 0.66 | PLAT (0.34) | SMN1; SMN2HTTALDH1A1HPGDGAA | |
| SCHEMBL16699234 | 0.66 | ADORA1 (0.48) | KDM4ESMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL16699755 | 0.66 | PLAT (0.34) | KDM4ESMN1; SMN2HTTALDH1A1PDE4D | |
| SCHEMBL16708910 | 0.65 | ALDH1A1 (0.44) | KDM4ESMN1; SMN2HTTALDH1A1HPGD | |
| SCHEMBL16700427 | 0.65 | KMT2A (0.37) | KDM4EL3MBTL1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL16699704 | 0.65 | CYP1A2 (0.36) | KDM4EL3MBTL1SMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | KDM4E 566/4885L3MBTL1 3554/4885SMN1; SMN2 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.